Webinar MINDFuL to FDA alignment XPro for the treatment of early AD

In this session, clinical experts and company leadership detail the strategic roadmap toward a Phase 3 program, highlighting recent alignment with the FDA on an integrated Phase 2b/3 study design. Learn how XPro™’s unique mechanism—targeting soluble TNF to reduce neuroinflammation—is being advanced through a precision medicine approach using biomarker-enriched patient populations. Key Topics Covered: Phase 2 MINDFuL Results: A review of clinical findings and biological data that informed the next steps for development. FDA Alignment: Details on the integrated Phase 2b/3 registration pathway and the use of CDR-SB as a primary endpoint. The Path to Phase 3: Strategies for global partnerships and maximizing XPro™’s potential for patients with early Alzheimer’s. Featured Speakers: Dr. Michael Woodward: Associate Professor at the Memory Clinic at Austin Health. Dr. Sharon Cohen: Medical Director at the Toronto Memory Program. For more information on INmune Bio’s immunology pipeline, visit: https://www.inmunebio.com #Alzheimers #Biotech #Neuroscience #ClinicalTrials #INmuneBio #XPro1595 #HealthcareInnovation